RxDoctor Payments Data

Aurelio Castrellon, MD

Hematology & Oncology · Pembroke Pines, FLNPI 1770792152

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $6,400 of the $7,561 with a category attached, or 84.6%. Pfizer accounts for 85.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $6,570 and has fallen 92.6% since, to $488 in 2025.

$7,561in general payments, 2019–2025

Across 42 payments — averaging $180.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • Daiichi Sankyo Inc.$521
  • AstraZeneca$196
  • Caris MPI, Inc.$152
  • Puma Biotechnology, Inc.$93
  • Johnson & Johnson$38
  • plus $124 from 7 others
$2,422,191in research payments, 2019–2025

Across 172 payments — averaging $14,083 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$1.9M
  • Genentech, Inc.$326K
  • Pfizer$199K
  • Puma Biotechnology, Inc.$30K
  • Seagen Inc.$5K

What the payments were for

  • Speaking & faculty fees$6,40085%
  • Food & beverage$1,11415%
  • Education$471%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,561 in reported general payments places this provider in the 55th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$43,682
Medicare patients
173
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib40$611,011
Letrozole260$5,518
Exemestane30$3,867
Ibandronate Sodium80$1,621
Anastrozole68$1,581
Raloxifene Hcl19$908
Ondansetron OdtOndansetron38$852
Alendronate Sodium78$495
Gabapentin27$306
Omeprazole31$209
Dicyclomine Hcl15$202
Lidocaine-PrilocaineLidocaine/Prilocaine11$146
Alprazolam28$134
Tramadol Hcl37$117
Oxycodone Hcl15$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$6,437$611,01140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →